Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization
Ram D. Bhatt, Peter Libby, Subodh Verma, et al.
Progress in Cardiovascular Diseases (2021) Vol. 69, pp. 3-10
Closed Access | Times Cited: 18

Showing 18 citing articles:

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Prakriti Gaba, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. 1660-1671
Open Access | Times Cited: 48
Omega-3 fatty acids for cardiovascular event lowering
Gurleen Kaur, R. Preston Mason, Philippe Gabríel Steg, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 8, pp. 1005-1014
Open Access | Times Cited: 15
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
Neila Sayah, Deepak L. Bhatt, Michael Miller, et al.
European Heart Journal (2024) Vol. 45, Iss. 13, pp. 1173-1176
Open Access | Times Cited: 11
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial
Rahul Aggarwal, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American Heart Association (2025)
Open Access | Times Cited: 1
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
Benjamin E. Peterson, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 6
Open Access | Times Cited: 35
Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT
Mark Rabbat, Suvasini Lakshmanan, Mina M. Benjamin, et al.
European Heart Journal - Cardiovascular Imaging (2023) Vol. 24, Iss. 7, pp. 866-873
Open Access | Times Cited: 19
Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae Nannochloropsis decreases plasma triglycerides and cholesterol in a real-world normolipidemic supplement consumer population
Eneko Ganuza, Eghogho H. Etomi, Magdalena Olson, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 4
Progress in Cardiovascular Diseases Statistics 2022
Carl J. Lavie
Progress in Cardiovascular Diseases (2022) Vol. 73, pp. 94-95
Closed Access | Times Cited: 18
Incremental benefits of combined inhibition of SGLT1 and SGLT2 with sotagliflozin
Ram D. Bhatt, Bertram Pitt, Philippe Gabríel Steg, et al.
Progress in Cardiovascular Diseases (2025)
Closed Access
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT
Prakriti Gaba, Deepak L. Bhatt, R. Preston Mason, et al.
Journal of clinical lipidology (2022) Vol. 16, Iss. 4, pp. 389-402
Open Access | Times Cited: 12
Cardiovascular statistics 2023
Carl J. Lavie
Progress in Cardiovascular Diseases (2023) Vol. 79, pp. 112-113
Closed Access | Times Cited: 4
Comparative evaluation of amino acid profiles, fatty acid compositions, and nutritional value of two varieties of head water Porphyra yezoensis: “Jianghaida No. 1” and “Sutong No.1”
Bin Guan, Yuyan Sun, Xuxiao Liu, et al.
Food Chemistry X (2024) Vol. 22, pp. 101375-101375
Open Access | Times Cited: 1
Impressive results with EPA, but EPA/DHA combinations also reduce cardiovascular outcomes
Carl J. Lavie, Aldo Bernasconi
Progress in Cardiovascular Diseases (2021) Vol. 69, pp. 110-112
Closed Access | Times Cited: 9
A decade as editor-in-chief of progress in cardiovascular diseases
Carl J. Lavie
Progress in Cardiovascular Diseases (2023) Vol. 76, pp. 118-119
Closed Access | Times Cited: 1
Protection against Incidences of Serious Cardiovascular Events Study with daily fish oil supplementation in dialysis patients (PISCES): protocol for a randomised controlled trial
Charmaine E. Lok, Brenda R. Hemmelgarn, Louise Moist, et al.
BMJ Open (2024) Vol. 14, Iss. 1, pp. e072239-e072239
Open Access
Nine Years as Editor-in Chief of Progress in Cardiovascular Diseases
Carl J. Lavie
Progress in Cardiovascular Diseases (2022) Vol. 70, pp. 195-196
Closed Access | Times Cited: 2
Killing the Culprit: Pharmacological Solutions to Get Rid of Cholesterol Crystals
Milad Iranshahy, Maciej Banach, Maede Hasanpour, et al.
Current Problems in Cardiology (2022) Vol. 47, Iss. 9, pp. 101274-101274
Closed Access | Times Cited: 1
Applications of Diacylglycerol Acyltransferase for Triacylglycerol Production in Mortierella alpina
Ruilin Yu, Lulu Chang, Jun Cao, et al.
Journal of Fungi (2023) Vol. 9, Iss. 2, pp. 219-219
Open Access
Page 1

Scroll to top